Director/PDMR Shareholding

ABCAM PLC

("Abcam" or "the Company")

Director and PDMR dealings

Cambridge, UK: Abcam plc (AIM: ABC), a global leader in the supply of protein research tools, was notified today that on 21 November 2011, the following transaction was undertaken by a Non-Executive Director of the Company:

Prof Tony Kouzarides sold 60,000 Ordinary Shares at a price of 352p per Ordinary Share in order to meet a tax liability.

Following this transaction, Prof Kouzarides' total beneficial interest in the Company is 341,220 Ordinary Shares, representing approximately 0.19 per cent of the current issued share capital of the Company. 

The Company was also notified today that on 21 November 2011, the following transaction was undertaken by a PDMR of the Company:

Dr Mark Bushfield exercised LTIP nil cost options over 30,000 Ordinary Shares at an exercise price of 0.2 pence per share, and subsequently sold 30,000 Ordinary Shares at a price of 352p per Ordinary Share.

Following these transactions, Dr Bushfield's total beneficial interest in the Company is 3,619 Ordinary Shares, representing approximately 0.002 per cent of the current issued share capital of the Company. 

For further information please contact:

Notes for editors:

About Abcam plc

Abcam is a producer and distributor of high quality protein research tools. These tools enable lifescientists to analyse components of living cells at the molecular level, which is essential in understanding health and disease.

Headquartered in Cambridge (UK), Abcam has subsidiary offices in Bristol (UK), Cambridge, MA (USA), Eugene, OR (USA), Tokyo (Japan) and Hong Kong (China) allowing it to serve a global customer base in over 85 countries. Abcam employs over 325 staff across its six operating companies.

Abcam now has an online catalogue of over 81,000 products sourced from over 300 suppliers. The catalogue includes a growing range of non-primary antibody products such as secondaries, proteins, peptides, lysates, immunoassays and other kits. Products are available for life science research and distributed to academic and commercial users. A highly developed eCommerce platform, which includes regional websites for the Chinese and Japanese markets, allows customers to access up-to-date and detailed technical product data sheets at the Company's website www.abcam.com.

Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company's vision is to be the leading provider of protein research tools globally.